Drug Trial Radar · NCT02446093
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Jan 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
54
Planned (sponsor's estimate)
Start
Oct 2015
Primary completion
Dec 2025
Study completion Jul 2026
Sponsor
- Lead sponsor
- Candel Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Mayo Clinic
- First posted
- May 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being treated with neoadjuvant chemoradiation (CR) or stereotactic body radiation therapy (SBRT). The Standard of Care (SOC) Control arm will be used as a benchmark for informal comparisons of efficacy, safety, and biomarkers.
Conditions
- Borderline Resectable Pancreatic Adenocarcinoma
Interventions
Aglatimagene besadenovecBiological
Three courses of CAN-2409 + prodrug (valacylovir or acyclovir) will be delivered and timed with different phases of therapy: 1) after induction chemotherapy 2) during CR or post-SBRT, and 3) at time of surgery. Up to 2 additional courses of CAN-2409 + prodrug, if feasible, for subjects with disease progression or metastases.
ChemoradiationRadiation
CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.
Stereotactic body radiation therapyRadiation
SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.
SurgeryProcedure
Surgical resection should be performed within 8 weeks after completing CR or SBRT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety grade by CTCAE version 4.0Time frame: From the time of CAN-2409 administration to 30 days after the last dose of valacyclovir.
- Survival RateTime frame: 24 months
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Lee Health/Regional Cancer Center
Fort Myers, Florida
Ohio State University
Columbus, Ohio
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.